TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01825473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel intra-luminal impedance (MII) pH monitoring

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multi-channel intra-luminal impedance (MII) pH monitoring

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)
Study: NCT03033992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
Description: The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent Optune and RT followed by Optune System alone
Description: In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
Study: NCT02632266

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Powder HMF
Description: powder human milk fortifier

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid HMF
Description: Liquid human milk fortifier
Study: NCT03828721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rx for Success Smartphone Application
Description: The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - screen time reduction
Description: Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
Study: NCT01754714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 2000 mg
Description: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
Study: NCT03549689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
Description: Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current tenofovir alafenamide (TAF)-containing ART regimen
Description: Continuation of current TAF-containing ART for 96 weeks.
Study: NCT04071002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks physical therapy programme
Description: The programme include contrast bath, bandage, massage, active exercises, resistive exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks physical therapy programme
Description: The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
Study: NCT06148129

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Biopsy
Description: The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
Study: NCT00650468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: IV or Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: IV or Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids (methylprednisone or prednisone)
Description: IV or Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids (methylprednisone or prednisone)
Description: IV or Oral
Study: NCT03584594

Intervention type: DIAGNOSTIC_TEST
Intervention: Presepsin measurement
Description: Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
Study: NCT03022851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlutech AFR Device
Description: Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
Study: NCT01231698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmolol
Description: Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: standard treatment without strict heart rate control
Study: NCT01702883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Survey
Description: prompt to complete internet survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Survey
Description: prompt to complete internet survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Survey
Description: prompt to complete internet survey
Study: NCT04424368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The remote monitoring system
Description: Usage of remote monitoring system
Study: NCT03117335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulijia
Description: Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Study: NCT02344186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Crossover design - 24 weeks on active drug and 12 weeks daily placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Crossover design - 24 weeks on active drug and 12 weeks daily placebo
Study: NCT00889122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame (DDR)
Description: Use of an active videogame vs. pedometers given to entire families to promote physical activity.
Study: NCT04241939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numberless BDS
Description: Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scale
Description: Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Motivational Interviewing
Description: Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
Study: NCT03290716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SS
Description: Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SS
Description: Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSSC
Description: A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSSC
Description: A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
Study: NCT02264223

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented red clover isoflavones in aglycone form
Description: Fermented isoflavones in aglycone form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented red clover isoflavones in aglycone form
Description: Fermented isoflavones in aglycone form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented red clover isoflavones in aglycone form
Description: Fermented isoflavones in aglycone form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented red clover isoflavones in aglycone form
Description: Fermented isoflavones in aglycone form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unfermented glycosides (as aglycone equivalents)
Description: Unfermented aglycone equivalents in glycoside form
Study: NCT01525082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine by mouth twice daily on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide by mouth daily on Days 10 to 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
Study: NCT03783923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
Study: NCT03906773

Intervention type: OTHER
Intervention: Patient Centered Medical Home Based Electronic Framework for Advance Care Planning
Description: The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
Study: NCT03987737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small urinary catheter placement in the rectum
Description: The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
Study: NCT01926301

Intervention type: PROCEDURE
Intervention: continuous veno-venous hemodialysis
Study: NCT04169425

Intervention type: PROCEDURE
Intervention: elective diverting ileostomy
Study: NCT03461029

Intervention type: DEVICE
Intervention: BIS monitor
Description: The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
Study: NCT01400373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehospital intra-nasal cooling with RhinoChill
Description: Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
Study: NCT02534207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
Study: NCT04333199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timely
Description: Email
Study: NCT02391922

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First aid course
Study: NCT04333199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timely
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transparency
Description: Email
Study: NCT04125693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
Study: NCT04333199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot-in-the-door
Description: Email
Study: NCT00116129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutamoren Mesylate (MK-0677)
Description: Ibutamoren Mesylate 25 mg/day
Study: NCT02554344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
Study: NCT03273712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA tyr3-Octreotide
Description: 90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan
Description: 68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
Study: NCT01900392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
Study: NCT03300232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based VC-CBT
Description: Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Product
Description: cosyntropin injection is given twice per Inpatient Stay
Study: NCT04242368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Nasal Wash
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Nasal Wash
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone nasal spray administered two sprays to each nare twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone nasal spray administered two sprays to each nare twice a day
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Luteinizing Hormone
Description: Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Injection
Description: Hydrocortisone IV push is given twice per Inpatient Visit
Study: NCT04125693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
Study: NCT02992639

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants who included in control group did not receive any treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss group
Description: The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
Study: NCT04504877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol 300 mg daily for 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Description: Cannabidiol 300 mg daily for 4 weeks
Study: NCT04483453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXPL feeding regimen
Description: EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTRL feeding regimen
Description: CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
Study: NCT01103206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: Intake of a single tablet of cinacalcet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet dose 1
Description: PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet dose 2
Description: Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
Study: NCT01887431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare
Description: Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
Study: NCT01531062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sative
Description: Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
Study: NCT01887431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: 3-month routine clinic visits
Study: NCT01531062

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black sticky rice
Description: 300 mg capsule bid, 56 days
Study: NCT02936479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-INH (Berinert)
Study: NCT02038738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
Study: NCT03694548

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Part A Survey
Description: Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Part A Survey
Description: Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part B Yoga Program
Description: Eight in-person instructor-led group yoga sessions.
Study: NCT02350959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
Study: NCT02449759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Intervention Group
Description: A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
Study: NCT00005879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arzoxifene
Description: one tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched tablet dialy
Study: NCT01103401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tobramycin 0.3% - Dexamethasone 0.1%
Description: one drop four times per day